Loading
x
This website uses essential cookies. With your consent, we place Google Analytics cookies for statistics.

Cookie Policy for Slzii.com

This is the Cookie Policy for Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact

Search (News)

先健科技公布2025年度业绩:营业收入增长稳健,扣非净利润劲增24.9%
深圳 2026年3月31日 /美通社/ -- 2026年3月31日,领先的心脑血管及外周血管介入医疗器械公司——先健科技公司("本公司"或"先健科技",股份代号:1302.HK)及其附属公司("本集团")公布截至2025年12月31日止年度("报告期内")的经审核综合业绩: 营收稳健: 实现营业收入约人民币1,369.8百万元,同比稳中上涨约5.1%,主要得益于销售覆膜支架的收入较去年同期增幅明显,达约19.9%; 盈利可观: 实现毛利约人民币1,019.1百万元,同比稳定增长约3.8%;毛利率约74.4%;剔除若干非经常性项 目 [1] ,净利润约为人民币353.4百万元,同比劲增约24.9%; 现金充裕: 截至2025年12月31日,现金及现金等价物约为人民币719.3百万元,较2024年12月31日增加约8.0%。 注释:【1】上述非经常性项目包括:1)以股份为基础的付款开支;2)按公平值计入损益的金融资产所产生的其他收益及亏损;3)与元心科技(深圳)有限公司可赎回股份有关的按公平值计入损益的金融负债之公平值变动。 国内市场稳中有增,海外业务较快增长 2025年,本集团在复杂多变的市场环境中稳步前行,持续巩固国内市场领先地位,并加速拓展国际市场。在「创新」与「国际化」双轮驱动的核心战略引领下,本集团深度聚焦全球未被满足的临床治疗需求,凭借覆盖全球各地的销售网络充分释放品牌、专利、渠道、临床注册及全球化运营的协同效应,以不断丰富和完善的创新产品组合与高质量学术服务,持续夯实长期发展基础,于报告期内实现国际、国内收入齐增。 其中,国内市场表现稳健,2025年录得销售额较去年同期增长约1.7%,占本集团总收入的权重约为71.1%;海外业务实现持续较快增长,录得销售额同比增长约14.4%,占本集团总收入的权重约为28.9%。尤其欧洲市场强劲增长约25.9%,跃升为本集团最大的海外市场,占本集团总收入的比重上升至约12.1%。 多元组合协同支撑 核心业务彰显韧性 本集团现有三条主要产品线,涵盖结构性心脏病业务、外周血管病业务及起搏电生理业务。 于报告期内,本集团实现营业收入约人民币1,369.8百万元,同比增加约5.1%,主要得益于外周血管病业务板块销售覆膜支架的收入较去年同期上涨约19.9%。 结构性心脏病业务: 本集团结构性心脏病业务产品组合多元化,主要包括左心耳封堵器及三代先天性心脏病封堵器,以通过差异化的产品策略满足不同的市场需求。于报告期内,本集团结构性心脏病业务贡献的销售额约为人民币511.7百万元,较去年同期减少约3.0%。 持续的技术创新和产品迭代升级将进一步丰富本集团结构性心脏病业务的产品组合,并优化其于全球市场的销售布局。 外周血管病业务: 本集团外周血管病业务所提供的产品主要包括腔静脉滤器、胸主动脉覆膜支架、腹主动脉覆膜支架、髂动脉分叉支架、主动脉覆膜支架系统、主动脉弓支架系统及胸腹主动脉覆膜支架系统。于报告期内录得销售额约为人民币844.6百万元,同比上升约12.4%。 本集团致力于为海内外患者提供技术领先的外周血管疾病系统性综合介入器械治疗方案,已率先构建全球行业领先的主动脉全腔内介入治疗整体解决方案,全面覆盖腔内重建弓部分支、内脏区分支及髂内动脉三大关键技术领域,这赋予了本集团外周血管病业务强大且持久的全球市场竞争力。 起搏电生理业务: 本集团为国产首家拥有达到国际级技术及功能的植入式心脏起搏器完整产品组合的生产厂商。于报告期内,本集团起搏电生理业务录得销售额约为人民币13.5百万元。 研发创新有序推进 战略管线稳步兑现 本集团坚持以自主创新为全球患者打造具备卓越临床价值的医疗器械产品。这不仅能够为患者和医生带来更优的疾病治疗方案,也为本集团的可持续发展带来长久的竞争力。 于报告期内,本集团研发投入(含资本化)为约人民币329.0百万元,占主营业务收入的比重约达24.0%,以持续加强技术创新能力,加速推进新产品的研发及商业化进程,截至2025年12月31日止年度取得以下成果: 【获批上市】 胸腹主动脉覆膜支架系统(包括G-BranchTM 胸腹主动脉主体覆膜支架系统、SilverFlowTM PV 外周血管覆膜支架系统、G-BranchTM AE 主体延长支架系统、G-BranchTM AAA分叉型主体支架系统及G-BranchTM IE 骼延长支架系统)、主动脉覆膜支架系统(包括AnkuraTM Pro主动脉主体覆膜支架系统及LonguetteTM主动脉分支覆膜支架系统)、主动脉弓支架系统(包括AnkuraTM Plus主动脉弓主体支架系统及CSkirtTM主动脉弓分支支架系统)、外周球囊扩张导管(大直径)、YoscopTM多环抓捕系统、SteerEaseTM-m心脏封堵器输送系统及左心耳封堵器输送系统 获国家药品监督管理局(NMPA)认证 ; AnkuraTM IIc大动脉覆膜支架系统 获CE MDR认证。 【注册审批中】 髂动脉覆膜支架系统(包括G-iliacTM Pro髂分叉覆膜支架系统及SilverFlowTM Pro髂内覆膜支架系统)、外周高压球囊扩张导管及YuranosTM Pro 腹主动脉覆膜支架系统等 正在中国注册审批中 ; 主动脉覆膜支架系统(包括AnkuraTM Pro主动脉主体覆膜支架系统及LonguetteTM主动脉分支覆膜支架系统)、FitayaTM腔静脉滤器系统、FuthroughTM大动脉覆膜支架球囊导管、YuranosTM腹主动脉覆膜支架系统、G-iliacTM髂动脉分叉支架系统、胸腹主动脉覆膜支架系统(包括G-BranchTM胸腹主动脉主体覆膜支架系统、SilverFlowTM PV外周血管覆膜支架系统、G-BranchTM AE主体延长支架系统、G-BranchTM AAA分叉型主体支架系统及G-BranchTM IE骼延长支架系统)及主动脉弓支架系统(包括AnkuraTM Plus主动脉弓主体支架系统及CSkirtTM主动脉弓分支支架系统) 正在CE认证中 ; 【提交注册申请】 IBS TitanTM可吸收药物洗脱外周支架系统处于中国和欧洲临床入组阶段,且其 已提交CE注册申请 ; IBSTM可吸收药物洗脱冠脉支架系统已完成II期临床研究的三年随访及III期临床研究的两年随访。目前,该产品 已提交CE及NMPA注册申请 ; 【临床随访中】 CeraTM 陶瓷膜卵圆孔未闭封堵器已在中国完成上市前临床入组, 正在进行临床随访 ; 【临床入组中】 CSTM 一体式弓部三分支重建系统、X-ClipTM经导管二尖瓣夹系统、SurechamTM主动脉弓单分支覆膜支架系统(包括主动脉弓单分支主体覆膜支架系统和主动脉分支血管覆膜支架系统)及镍钛合金动脉导管未闭封堵器 正处于中国注册前临床入组阶段 ; 【进入绿通】 镍钛合金动脉导管未闭封堵器 进入NMPA创新医疗器械特别审查程序, 为本公司 第16个 进入该程序的产品。 知识产权保驾护航 知识产权是本集团提升于医疗器械市场核心竞争力的内驱动力。本集团持续重视高质量的全球知识产权布局,截至2025年12月31日累计提交2,631项有效专利申请,其中1,217项已获注册。 深化战略合作,布局心脏电生理 于2025年6月6日,本集团透过全资附属公司先健科技(深圳)有限公司("先健深圳")与剑虎医疗科技(苏州)有限公司("剑虎医疗")订立系列协议,以现金合共人民币150.0百万元投资于剑虎医疗。在完成该投资的所有阶段后,先健深圳将拥有剑虎医疗30%的股权。于报告期内,先健深圳已完成第一阶段注资,代价为现金人民币100.0百万元,并持有剑虎医疗22.22%的股权。 通过该战略投资,本集团获得剑虎医疗电生理相关产品的独家优先合作权及海外独家经销权,双方亦将共同促进创新心脏介入影像平台产品的研究、开发及商业化,拓展了本集团在高增长医疗器械领域的业务,并将与本集团的现有业务产生显著的协同效应。 先健科技董事局主席兼首席执行官谢粤辉先生表示: 2025年,本集团 在全球行业变革与发展的浪潮中继续稳健前行。我们以强大的业务韧性为支撑,专业化布局协同发展,进一步稳固市场根基,持续深化业务的国际化进程,研发成果的临床转化亦取得阶段性成绩。同时,对剑虎医疗的战略投资,让我们成功驶入高增长心脏电生理市场的快车道,通过显著的协同效应为未来增长开辟新的空间。 我们始终锚定"创新"与"国际化"两大核心发展战略,以前瞻性布局加速创新产品的研发与临床应用,推动关键技术突破与产品迭代升级,以不断完善的系统化疾病解决方案满足多元的临床治疗需求,进一步激活本集团于全球市场的业务活力,以可持续的竞争优势稳步提升全球市场份额,牢筑行业领先地位。 面对全球医疗健康行业的广阔前景,本集团充满信心。凭借卓越的创新能力、稳固的产业基础和持续提升的全球影响力,我们有能力在复杂多变的市场环境中应对挑战,把握新的发展机遇,迈向可持续、高质量的增长新未来,以有意义的创新和深刻的社会效应为患者、医生、股东及各相关方创造更大价值!
2026-03-31 12:32:00

0.035710096359253


News
News

Latest News and Headlines
深圳 2026年3月31日 /美通社/ -- 2026年3月31日,领先的心脑血管及外周血管介入医疗器械公司——先健科技公司(本公司或先健科技,股份代号:1302.HK)及其附属公司(本集团)公布截至2025年12月31日止年度(报告期内)的经审核综合业绩: 营收...
News